secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0001493152-25-027914
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine's PPD Phase 3 study hits 80% enrollment; DSMB review in Jan 2026
-------------------------------------------------------------------------

- 66 of 80 planned participants randomized in Phase 3 trial of LPCN 1154 for postpartum depression.
- Second independent DSMB review planned for mid-January 2026; first review recommended continuation.
- Topline results expected Q2 2026; NDA submission under 505(b)(2) planned for 2026.
- Study conducted entirely outpatient; no medical monitoring required per FDA feedback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225027914/0001493152-25-027914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315225027914/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-027914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer